Premium
Strategic targeting of non‐small‐cell lung cancer utilizing genetic material‐based delivery platforms of nanotechnology
Author(s) -
Chaudhary Swati,
Singh Amit,
Kumar Pankaj,
Kaushik Mahima
Publication year - 2021
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.22784
Subject(s) - biodistribution , gene delivery , genetic enhancement , nanotechnology , drug delivery , nanomedicine , cancer , cancer therapy , in vivo , cancer research , nanoparticle , materials science , medicine , chemistry , biology , gene , microbiology and biotechnology , biochemistry
Abstract Several limitations of conventional cancer treatment such as non‐specific targeting, solubility problems, and ineffective entry of chemotherapeutics into cancer cells can be overcome by using nanotechnology targeted drug delivery systems. Some combinations of biomolecules and nanoparticles have proven to be excellent therapeutics for Non‐small cell lung cancer (NSCLC) in the last decades. Targeted gene delivery has shown in vivo as well as in vitro promising results with therapeutic efficacy. Gene therapy has shown enhanced transfection efficiency and better targeting potential on several NSCLC cell lines. Still, there are several challenges in nanoparticle‐mediated gene therapy, which include stability of biomolecules and nanoparticles during delivery, managing their biodistribution, and reducing the possible cytotoxic effects of the nanoparticles, which need to be solved before clinical trials. Evaluation of therapeutic efficacy of biomolecules and nanoparticle combination in gene therapy must be established to expand the application of nano‐gene therapy in cancer treatment.